NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the following upcoming investor conferences:
